胰高血糖素样肽-2在小鼠和人类移植物抗宿主病中促进肠道干细胞和潘氏细胞修复
急性移植物抗宿主病(GVHD)是异基因造血细胞移植后的致命并发症。研究观察发现急性GVHD降低小鼠和患者肠道GLP-2水平;使用GLP-2激动剂替度鲁肽可减少小鼠急性GVHD和激素难治性GVHD且不损害移植物抗白血病效应,机制上促进潘氏细胞和肠道干细胞再生。低L细胞数量和高血清GLP-2水平与allo-HCT患者非复发死亡率较高相关。
要点
- 急性GVHD降低小鼠和患者肠道GLP-2水平。
- 替度鲁肽减少小鼠急性GVHD和激素难治性GVHD,不损害移植物抗白血病效应。
- GLP-2促进潘氏细胞和肠道干细胞再生,增强抗菌肽产生并改变微生物组。
核心结论
- L细胞是GVHD的靶点,基于GLP-2的治疗通过增加肠道干细胞和潘氏细胞恢复肠道稳态而不损害移植物抗白血病效应。
- 替度鲁肽可能成为免疫抑制GVHD治疗的新联合伙伴,有待临床试验测试。
研究设计与样本
- 研究在小鼠模型和人类患者中探索GLP-2对肠道干细胞和潘氏细胞的保护与再生作用。
主要发现
- 急性GVHD降低小鼠和发生GVHD患者的肠道GLP-2水平。
- 替度鲁肽在多个小鼠模型中减少新发急性GVHD和激素难治性GVHD,且不损害移植物抗白血病效应。
- GLP-2替代促进潘氏细胞和肠道干细胞再生,增强抗菌肽产生并引起微生物组变化。
- GLP-2扩增肠道类器官并降低凋亡相关基因表达。
- 肠道活检中低L细胞数量和高血清GLP-2水平与接受allo-HCT患者较高的非复发死亡率发生率相关。
临床怎么用
- 替度鲁肽可能成为免疫抑制GVHD治疗的新联合伙伴,有待临床试验测试。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute graft-versus-host disease (GVHD) is a life-threatening complication after allogeneic hematopoietic cell transplantation (allo-HCT). Although currently used GVHD treatment regimens target the donor immune system, we explored here an approach that aims at protecting and regenerating Paneth cells (PCs) and intestinal stem cells (ISCs). Glucagon-like-peptide-2 (GLP-2) is an enteroendocrine tissue hormone produced by intestinal L cells. We observed that acute GVHD reduced intestinal GLP-2 levels in mice and patients developing GVHD. Treatment with the GLP-2 agonist, teduglutide, reduced de novo acute GVHD and steroid-refractory GVHD, without compromising graft-versus-leukemia (GVL) effects in multiple mouse models. Mechanistically GLP-2 substitution promoted regeneration of PCs and ISCs, which enhanced production of antimicrobial peptides and caused microbiome changes. GLP-2 expanded intestinal organoids and reduced expression of apoptosis-related genes. Low numbers of L cells in intestinal biopsies and high serum levels of GLP-2 were associated with a higher incidence of nonrelapse mortality in patients undergoing allo-HCT. Our findings indicate that L cells are a target of GVHD and that GLP-2-based treatment of acute GVHD restores intestinal homeostasis via an increase of ISCs and PCs without impairing GVL effects. Teduglutide could become a novel combination partner for immunosuppressive GVHD therapy to be tested in clinical trials.
引用
- Norona J, Apostolova P, Schmidt D, et al. Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. Blood. 2020. PMID: 32542357. doi:10.1182/blood.2020005957
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。